COMMUNIQUÉS West-GlobeNewswire

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
26/01/2026
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical- [...]
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
26/01/2026
New Record Financial Results: Total revenues of $30.1 million, gross profit before fair value adjustments of $13.5 million or 45% and Adjusted EBITDA of $8.8 million 1 , supported by operating cash flows of $8.0 million [...]
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of [...]
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026
Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminated Improved profitability and early Q-Cog reimbursement activity position the Company for [...]
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026
MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- BlueOcean Global Corp., a medical device company focused on limb preservation and complex reconstruction, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance [...]
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
26/01/2026
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind [...]
Nxera Pharma Webinar Presentation for FY2025 Financial Results
26/01/2026
Tokyo, Japan and Cambridge, UK, 26 January 2026 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2025 on Friday, 13 February [...]
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
HighLife Receives CE Mark Approval for its TMVR Solution Paris, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has [...]
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
HighLife Receives CE Mark Approval for its TMVR Solution Paris, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/01/2026
COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
Lake Erie College of Osteopathic Medicine Designs Medical Education Around Multiple Learning Pathways to Support Different Learning Styles
26/01/2026
Erie, PA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Medical education is often delivered through a single instructional format, but Lake Erie College of Osteopathic Medicine (LECOM) is taking a different approach by designing [...]
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
26/01/2026
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
26/01/2026
ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
26/01/2026
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May [...]
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
25/01/2026
First surgeon-reported case using RECELL ® , PermeaDerm ® , and Cohealyx ™ together in a single care pathway New clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness [...]
University Medical Center Southern Nevada Becomes First Hospital in Nevada to Earn Magnet Recognition
24/01/2026
Prestigious designation recognizes excellence in nursing, patient care, and clinical outcomes LAS VEGAS, Jan. 24, 2026 (GLOBE NEWSWIRE) -- University Medical Center Southern Nevada (UMC) has achieved Magnet® designation [...]
Direct Meds NAD+ Injections Consumer Report 2026: Comparing Supplement and Peptide Alternatives, Dosage, Benefits & Side Effects
24/01/2026
A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+ benefits, and potential NAD+ side effects New York, NY, Jan. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/01/2026
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
23/01/2026
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business [...]

Pages